XML 22 R14.htm IDEA: XBRL DOCUMENT v3.22.4
Note 8 - Investments in Marketable Securities
3 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]

Note 8 - Investments in Marketable Securities

 

All investments are classified as “Current assets” because they are available for sale at any time. These “available-for-sale” marketable securities are stated at fair value. The Company uses quoted prices in active markets for identical assets (consistent with the Level 1 definition in the fair value hierarchy) to measure the fair value of its investments on a recurring basis pursuant to ASC 820, Fair Value Measurement. As of December 31, 2022 and September 30, 2022, there were net accumulated pretax unrealized gains of $144,717,000 and $120,692,000, respectively, recorded in the accompanying Consolidated Balance Sheets. Most of the accumulated pretax unrealized gains were in the common stocks of three U.S. financial institutions and one foreign manufacturer.

 

In December 2022, the Company recorded and included in its net income the net unrealized gains on marketable securities of $24,025,000, as compared with the net unrealized losses on marketable securities of $36,088,000, in the prior year period.

 

In December 2022, the Company sold part of its marketable securities for approximately $2,826,000, realizing net gains of $422,000, and borrowed an additional $6,011,000 from the margin loan account to purchase additional marketable securities with a total cost of approximately $10,001,000.

 

In December 2021, the Company sold part of its marketable securities for approximately $50,020,000, realizing gains of $46,694,000, and borrowed an additional $37,014,000 from the margin loan account to purchase additional marketable securities with a total cost of approximately $87,125,000.

 

Investments in marketable securities as of December 31, 2022 and September 30, 2022 are summarized below.

 

Investment in Financial Instruments

 

   

December 31, 2022

   

September 30, 2022

 
   

Aggregate

fair value

   

Amortized/

Adjusted

cost basis

   

Pretax

unrealized

gains

   

Aggregate

fair value

   

Amortized/

Adjusted

cost basis

   

Pretax

unrealized

gains

 

Marketable securities

                                               

Common stocks

  $ 307,151,000     $ 162,434,000     $ 144,717,000     $ 275,529,000     $ 154,837,000     $ 120,692,000